TitleAssistant Professor
InstitutionMD Anderson
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Deng M, Tan J, Fan Z, Pham LV, Zhu F, Fang X, Zhao H, Young K, Xu B. The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. Sci Rep. 2023 10 29; 13(1):18554. PMID: 37899423; PMCID: PMC10613613.
      Citations: 1     Fields:    Translation:HumansCells
    2. Yu F, He H, Nastoupil LJ, Xu-Monette ZY, Pham K, Liang Y, Chen G, Fowler NH, Yin CC, Tan D, Yang Y, Hu S, Young KH, Pham LV, You MJ. Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma. Am J Cancer Res. 2022; 12(10):4666-4679. PMID: 36381323; PMCID: PMC9641390.
      Citations: 1     
    3. Yuan D, Li G, Yu L, Jiang Y, Shi Y, Chen Q, Ma X, Pham LV, Young KH, Deng M, Fang Z, Xu B. CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements. Front Oncol. 2021; 11:618908. PMID: 33777762; PMCID: PMC7988232.
      Citations: 1     
    4. Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, Zhu F, Visco C, Bhagat G, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, You H, Huh J, Ponzoni M, Parsons BM, Hagemeister F, van Krieken JH, Winter JN, Li Y, Xu B, Liu P, Young KH, Ferreri AJM, M?ller MB, Piris MA. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260. PMID: 33154093; PMCID: PMC8092941.
      Citations: 5     Fields:    Translation:HumansCells
    5. Deng M, Zhang M, Xu-Monette ZY, Pham LV, Tzankov A, Visco C, Fang X, Bhagat G, Zhu F, Dybkaer K, Chiu A, Tam W, Zu Y, Hsi ED, Choi WWL, Huh J, Ponzoni M, Parsons BM, van Krieken JH, Winter JN, Hagemeister F, Alinari L, Li Y, Andreeff M, Xu B, Young KH, Ferreri AJM, M?ller MB, Piris MA. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148. PMID: 33148342; PMCID: PMC7641823.
      Citations: 10     Fields:    Translation:HumansCells
    6. Liu Y, Azizian NG, Dou Y, Pham LV, Li Y. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J Hematol Oncol. 2019 11 21; 12(1):119. PMID: 31752970; PMCID: PMC6868798.
      Citations: 7     Fields:    Translation:Humans
    7. Azizian NG, Liu Y, Pham LV, Li Y. Rational targeted therapeutics for double-hit lymphoma. Int J Hematol Oncol. 2019 Aug 21; 8(3):IJH19. PMID: 31850145; PMCID: PMC6912852.
    8. Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L, Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019 05 08; 11(491). PMID: 31068440.
      Citations: 61     Fields:    Translation:AnimalsCells
    9. Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH, Rodr?guez-Perales S, Dybk?r K, Ferreri AJM, M?ller MB, Piris MA. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657. PMID: 30745366.
      Citations: 44     Fields:    Translation:HumansCells
    10. Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Ngo VN, M?schen M. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. 2019 01 24; 133(4):306-318. PMID: 30530749; PMCID: PMC6347093.
      Citations: 9     Fields:    Translation:HumansCells
    11. Ren Y, Bi C, Zhao X, Lwin T, Wang C, Yuan J, Silva AS, Shah BD, Fang B, Li T, Koomen JM, Jiang H, Chavez JC, Pham LV, Sudalagunta PR, Wan L, Wang X, Dalton WS, Moscinski LC, Shain KH, Vose J, Cleveland JL, Sotomayor EM, Fu K, Tao J. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018 12 03; 128(12):5517-5530. PMID: 30260324; PMCID: PMC6264635.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    12. Li L, Zhang J, Chen J, Xu-Monette ZY, Miao Y, Xiao M, Young KH, Wang S, Medeiros LJ, Wang M, Ford RJ, Pham LV. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018 10 25; 132(17):1805-1817. PMID: 30209121; PMCID: PMC6634963.
      Citations: 29     Fields:    Translation:HumansCells
    13. Pham LV, Pogue E, Ford RJ. The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas. Front Oncol. 2018; 8:147. PMID: 29868471; PMCID: PMC5951963.
      Citations: 18     
    14. Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018 08 15; 24(16):3967-3980. PMID: 29666304.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    15. Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE, Hu S, Medeiros LJ, Ford RJ, Pham LV. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget. 2018 Jan 02; 9(1):346-360. PMID: 29416618; PMCID: PMC5787470.
      Citations: 5     Fields:    
    16. Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Wang S, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH, Dybk?r K, Ferreri AJM, M?ller MB. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716. PMID: 28627414; PMCID: PMC5530910.
      Citations: 21     Fields:    Translation:HumansCells
    17. Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res. 2017 Aug 01; 23(15):4212-4223. PMID: 28348046; PMCID: PMC5540787.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    18. Medeiros LJ, Chen Z, Chen W, Li S, Konoplev SN, Lu X, Pham LV, Young KH, Wang W, Hu S, Hu Z. Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients. Am J Surg Pathol. 2017 Feb; 41(2):216-224. PMID: 27776009.
      Citations: 16     Fields:    Translation:Humans
    19. Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH, Ferreri AJ, M?ller MB. RelA NF-?B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging (Albany NY). 2016 12 08; 8(12):3321-3340. PMID: 27941215; PMCID: PMC5270671.
      Citations: 13     Fields:    Translation:HumansCells
    20. Pham LV, Bryant JL, Mendez R, Chen J, Tamayo AT, Xu-Monette ZY, Young KH, Manyam GC, Yang D, Medeiros LJ, Ford RJ. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 06; 7(49):80599-80611. PMID: 27716624; PMCID: PMC5348344.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    21. Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 2016 Nov 08; 7(45):73558-73572. PMID: 27713153; PMCID: PMC5341999.
      Citations: 23     Fields:    Translation:HumansCells
    22. Pham LV, Lu G, Tamayo AT, Chen J, Challagundla P, Jorgensen JL, Medeiros LJ, Ford RJ. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC. J Hematol Oncol. 2015 Oct 29; 8:121. PMID: 26515759; PMCID: PMC4627381.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    23. Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KH, Ferreri AJ, M?ller MB. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Sep 15; 6(27):23157-80. PMID: 26324762; PMCID: PMC4695110.
      Citations: 21     Fields:    Translation:HumansCells
    24. Yang DJ, Pham L, Liao MH, Kong FL, Uemura H, Shih YY. Advances in molecular pathway-directed cancer systems imaging and therapy. Biomed Res Int. 2014; 2014:639475. PMID: 25587538; PMCID: PMC4283426.
      Citations: 1     Fields:    Translation:Humans
    25. Pham LV, Vang MT, Tamayo AT, Lu G, Challagundla P, Jorgensen JL, Rollo AA, Ou Z, Zhang L, Wang M, Ford RJ. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma. 2015 Jan; 56(1):186-93. PMID: 24611650; PMCID: PMC5779854.
      Citations: 6     Fields:    Translation:HumansCells
    26. Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013 Nov; 12(11):2494-504. PMID: 23990113.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    27. Zhang K, Wang M, Tamayo AT, Shacham S, Kauffman M, Lee J, Zhang L, Ou Z, Li C, Sun L, Ford RJ, Pham LV. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013 Jan; 41(1):67-78.e4. PMID: 22986101.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    28. Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochem Pharmacol. 2012 Aug 15; 84(4):451-8. PMID: 22687624.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    29. Li C, Thompson MA, Tamayo AT, Zuo Z, Lee J, Vega F, Ford RJ, Pham LV. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget. 2012 Mar; 3(3):314-26. PMID: 22447839; PMCID: PMC3359887.
      Citations: 37     Fields:    Translation:HumansCells
    30. Pham LV, Ford RJ. The role of BAFF-R dysregulation in B-lymphoid lineage malignancies. Cell Cycle. 2011 Jan 15; 10(2):189-90. PMID: 21239884.
      Citations: 2     Fields:    Translation:HumansCells
    31. Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, Vega F, Medeiros LJ, Ford RJ. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-?B-inducing kinase while activating both canonical and alternative nuclear factor-?B pathways. Blood. 2011 Jan 06; 117(1):200-10. PMID: 20889926; PMCID: PMC3037744.
      Citations: 34     Fields:    Translation:HumansCells
    32. Pham LV, Tamayo AT, Li C, Bueso-Ramos C, Ford RJ. An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas. Blood. 2010 Nov 11; 116(19):3899-906. PMID: 20664054; PMCID: PMC2981542.
      Citations: 22     Fields:    Translation:HumansCells
    33. Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther. 2010 Jul; 9(7):2026-36. PMID: 20606045; PMCID: PMC5483974.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    34. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R, Rader C, Muthusamy N, Johnson AJ, Byrd JC. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010 Apr 01; 115(13):2619-29. PMID: 19965642; PMCID: PMC2852364.
      Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
    35. Vega F, Davuluri Y, Cho-Vega JH, Singh RR, Ma S, Wang RY, Multani AS, Drakos E, Pham LV, Lee YC, Shen L, Ambrus J, Medeiros LJ, Ford RJ. Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination. J Cell Mol Med. 2010 Jun; 14(6B):1532-45. PMID: 19656242; PMCID: PMC3829019.
      Citations: 9     Fields:    Translation:AnimalsCells
    36. Fu L, Lin-Lee YC, Pham LV, Tamayo AT, Yoshimura LC, Ford RJ. BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood. 2009 May 07; 113(19):4627-36. PMID: 19258594; PMCID: PMC2680367.
      Citations: 44     Fields:    Translation:HumansCells
    37. Pham LV, Zhou HJ, Lin-Lee YC, Tamayo AT, Yoshimura LC, Fu L, Darnay BG, Ford RJ. Nuclear tumor necrosis factor receptor-associated factor 6 in lymphoid cells negatively regulates c-Myb-mediated transactivation through small ubiquitin-related modifier-1 modification. J Biol Chem. 2008 Feb 22; 283(8):5081-9. PMID: 18093978.
      Citations: 14     Fields:    Translation:HumansCells
    38. Zhou HJ, Pham LV, Tamayo AT, Lin-Lee YC, Fu L, Yoshimura LC, Ford RJ. Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood. 2007 Sep 15; 110(6):2121-7. PMID: 17567982; PMCID: PMC1976364.
      Citations: 15     Fields:    Translation:HumansCells
    39. Yang HY, Wen YY, Lin YI, Pham L, Su CH, Yang H, Chen J, Lee MH. Roles for negative cell regulator 14-3-3sigma in control of MDM2 activities. Oncogene. 2007 Nov 15; 26(52):7355-62. PMID: 17546054.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    40. Ford RJ, Shen L, Lin-Lee YC, Pham LV, Multani A, Zhou HJ, Tamayo AT, Zhang C, Hawthorn L, Cowell JK, Ambrus JL. Development of a murine model for blastoid variant mantle-cell lymphoma. Blood. 2007 Jun 01; 109(11):4899-906. PMID: 17311992; PMCID: PMC1885517.
      Citations: 11     Fields:    Translation:AnimalsCells
    41. Lin-Lee YC, Pham LV, Tamayo AT, Fu L, Zhou HJ, Yoshimura LC, Decker GL, Ford RJ. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem. 2006 Jul 07; 281(27):18878-87. PMID: 16644731.
      Citations: 19     Fields:    Translation:HumansCells
    42. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006 Jun 01; 107(11):4540-8. PMID: 16497967; PMCID: PMC1895801.
      Citations: 63     Fields:    Translation:HumansCells
    43. Pham LV, Tamayo AT, Yoshimura LC, Lin-Lee YC, Ford RJ. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood. 2005 Dec 01; 106(12):3940-7. PMID: 16099873; PMCID: PMC1895110.
      Citations: 63     Fields:    Translation:HumansCells
    44. Rangel R, McKeller MR, Sims-Mourtada JC, Kashi C, Cain K, Wieder ED, Molldrem JJ, Pham LV, Ford RJ, Yotnda P, Guret C, Martinez-Valdez H, Franc?s V. Assembly of the kappa preB receptor requires a V kappa-like protein encoded by a germline transcript. J Biol Chem. 2005 May 06; 280(18):17807-14. PMID: 15757909.
      Citations: 5     Fields:    Translation:HumansCells
    45. Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 2003 Aug; 88(8):853-63. PMID: 12935973.
      Citations: 19     Fields:    Translation:HumansCells
    46. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003 Jul 01; 171(1):88-95. PMID: 12816986.
      Citations: 93     Fields:    Translation:HumansCells
    47. Bryant J, Pham L, Yoshimura L, Tamayo A, Ordonez N, Ford RJ. Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models. Lab Invest. 2000 Apr; 80(4):557-73. PMID: 10780672.
      Citations: 1     Fields:    Translation:HumansAnimals
    48. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC. Journal of Hematology and Oncology.
    49. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 7:73558-73572.
    50. Mantle Cell Lymphoma With MYC Rearrangement. American Journal of Surgical Pathology.
    51. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 6:23157-23180.
    52. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 6:5597-5614.
    53. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 7:80599-80611.
    PHAM's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (294)
    Co-Authors (37)
    Similar People (60)
    Same Department Expand Description